論文・総説​​​

​

・Uekusa S, Nakashin M, Hanai Y, Nemoto M, Yanagino S, Arita Y, Matsumoto T, Wakui N, Nagai H, Higai K, Matsuo K.Risk factors for lenvatinib-induced hypertension in patients with hepatocellular carcinoma: A retrospective study. Br J Clin Pharmacol. 2025 Mar;91(3):894-902. doi: 10.1111/bcp.16337.

​

・Nagumo H, Nagai H, Higai K, Matsuda T, Igarashi Y. Effects of Atezolizumab plus Bevacizumab on Skeletal Muscle Volume and Cardiac Function in Patients with Hepatocellular Carcinoma.Oncology. 2025;103(5):369-379. doi: 10.1159/000541674.

​

・Mukozu T, Nagai H, Nagumo H, Mohri K, Yoshimine N, Kobayashi K, Ogino Y, Matsui T, Daido Y, Wakui N, Momiyama K, Higai K, Matsuda T, Igarashi Y. The Usefulness of Serum Interleukin-6 as a Predictor of Response to Atezolizumab plus Bevacizumab Combination Treatment in Hepatocellular Carcinoma.Oncology. 2025;103(4):277-289. doi: 10.1159/000541372.

​

・Kato A, Nihei W, Yako H, Tatsumi Y, Himeno T, Kondo M, Kato Y, Nakamura J, Kamiya H, Sango K, Kato K. Imeglimin improves hyperglycemia and hypoglycemia-induced cell death and mitochondrial dysfunction in immortalized adult mouse Schwann IMS32 cells.  J Diabetes Investig​. 2025 Sep;16(9):1586-1596.  doi: 10.1111/jdi.70092.